Payment overview · 2025
General Payments
$52,903.32
81 reported records · 12 companies
Healthcare provider profile · identity verified
Bernardo Curi Mendes, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · LOS ANGELES, CA · NPI 1760814891
Verified facts
What the public records show
CMS Open Payments records show Bernardo Curi Mendes, MD received $52,903.32 in general payments during 2025 across 81 reported records.
Cook Incorporated accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cook Incorporated | Unresolved — no canonical attribution shown | $22,383.30 | 42.3% | 8 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $19,318.19 | 36.5% | 24 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$7,136.96 | 13.5% | 24 | 2025 |
| Artivion, Inc. | Unresolved — no canonical attribution shown | $2,359.38 | 4.5% | 4 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $524.51 | 1.0% | 8 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $309.05 | 0.6% | 4 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $279.15 | 0.5% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $221.67 | 0.4% | 2 | 2025 |
| Balt USA, LLC | Unresolved — no canonical attribution shown | $151.32 | 0.3% | 2 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $150.00 | 0.3% | 1 | 2025 |
| Cook Research Incorporated | Unresolved — no canonical attribution shown | $49.86 | 0.1% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $19.93 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $24,287.50 | 7 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,020.00 | 4 |
| Travel and Lodging | $9,133.10 | 15 |
| Food and Beverage | $4,162.72 | 52 |
| Honoraria | $2,300.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $15,491.21 | 11 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Stent Graft Normalized: gore tag conformable thoracic stent graft |
Device | W. L. Gore & Associates, Inc. | $14,479.87 | 5 | 2025 |
Source payment records
|
|||||
| ZENITH ALPHA Normalized: zenith alpha |
Device | Cook Incorporated, Cook Medical LLC | $9,483.69 | 7 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Incorporated, Cook Medical LLC, Cook Research Incorporated | $9,005.91 | 8 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $5,390.21 | 4 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $3,057.58 | 5 | 2025 |
Source payment records
|
|||||
| Jotec Products Normalized: jotec products |
Device | Artivion, Inc. | $2,300.00 | 3 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $1,662.90 | 18 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $309.05 | 4 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $287.45 | 2 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Endoprosthesis Normalized: gore tag thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $193.05 | 2 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $165.55 | 2 | 2025 |
Source payment records
|
|||||
| THORAFLEX HYBRID Normalized: thoraflex hybrid |
Device | Bolton Medical Inc | $157.38 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $155.72 | 1 | 2025 |
Source payment records
|
|||||
| Prestige Coil System Normalized: prestige coil system |
Device | Balt USA, LLC | $151.32 | 2 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $122.31 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $83.85 | 2 | 2025 |
Source payment records
|
|||||
| AMDS-Ascyrus Medical Normalized: amds ascyrus medical |
Device | Artivion, Inc. | $59.38 | 1 | 2025 |
Source payment records
|
|||||
| ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER Normalized: on x aortic heart valve with conform x sewing ring and extended holder |
Device | Artivion, Inc. | $59.38 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $19.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52,903.32 · 81 records | Cook Incorporated | AMDS-Ascyrus Medical, CGuard Prime Carotid Stent System, ENDURANT IIS, EXCLUDER Conformable AAA Endoprosthesis with Active Control, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Endoprosthesis, GORE TAG Conformable Thoracic Stent Graft, GORE TAG Thoracic Branch Endoprosthesis, GORE TAG Thoracic Endoprosthesis, IMPEDE EMBOLIZATION PLUG, Jotec Products, ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER, Prestige Coil System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, THORAFLEX HYBRID, TREO ABDOMINAL STENT-GRAFT SYSTEM, VALIANT CAPTIVIA, VENASEAL, ZENITH ALPHA, ZENITH SPIRAL-Z | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error